04 Apr 2016
LIBERUM: Shield Therapeutics - Initiation: Late stage, high potential spec pharma
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
LIBERUM: Shield Therapeutics - Initiation: Late stage, high potential spec pharma
Shield Therapeutics Plc (STX:LON) | 2.0 0 0.0% | Mkt Cap: 15.8m
- Published:
04 Apr 2016 -
Author:
Roger Franklin | Dominic Rose | Naresh Chouhan -
Pages:
70